Sanofi’s Kadmon Bolt-On Bolsters Its General Medicine Division
Deal Adds Transplant Pill Rezurock For Chronic Graft-Versus-Host Disease
Sanofi’s $1.9bn cash purchase of Kadmon surprised many analysts, coming as a bolt-on for the French pharma’s general medicines transplant portfolio rather than its specialty care pipeline, but the overall view was that it made sense.
You may also be interested in...
Sanofi’s general medicines business will embrace an omnichannel commercial model in 2022 to reduce inefficiencies and stabilize topline growth. Virtual sales reps are on the rise after a tough couple of years managing product promotion and launches online only.
As well as buying Origimm, the French giant will also apply its mRNA vaccine platform, acquired through the recent $3.2bn acquisition of Translate Bio, to discover and develop other acne vaccines, aided by the Vienna-headquartered firm's know-how in the field.
Sanofi is on a roll thanks to Dupixent and the blockbuster is providing breathing space even when some key pipeline assets are delayed.